The long-term use of felbamate in children with severe refractory epilepsy

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology

Background:

• Severe, uncontrolled epilepsy in children presents significant treatment challenges.
• Refractory epilepsy often requires exploring add-on antiepileptic drug therapies.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of felbamate (FBM) as adjunctive treatment for severe pediatric epilepsy.
• To assess FBM's effectiveness across different epilepsy syndromes in children.

Main Methods:

• A 3-year follow-up study involving 36 pediatric patients with severe uncontrolled epilepsy.
• Felbamate (FBM) was titrated weekly up to 45 mg/kg, with regular hematological and biochemical monitoring.
• Efficacy was measured by seizure frequency reduction (>50%) at various time points.

Main Results:

• Overall efficacy, defined as >=50% seizure reduction, decreased from 69% at 3 months to 41% at 3 years.
• Felbamate (FBM) demonstrated effectiveness in various epilepsy types, particularly simple partial, tonic, and atonic seizures.
• One-third of patients maintained substantial seizure control for at least 3 years.
• Frequent adverse events included anorexia, weight loss, urinary retention, somnolence, nervousness, and insomnia.

Conclusions:

• Felbamate (FBM) can be an effective add-on therapy for a broad spectrum of refractory pediatric epilepsies.
• While initial efficacy wanes over time, a significant proportion of patients benefit long-term.
• Careful monitoring for adverse events is crucial during felbamate (FBM) treatment in children.